1 month Rifapentine, Isoniazid and Vitamin B6 for Latent Tuberculosis

Phase-Based Progress Estimates
3
Effectiveness
3
Safety
Pinki J Bhatt, New Brunswick, NJ
Latent Tuberculosis+6 More
Rifapentine - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This is a prospective, single-center, single-arm, open-label study investigating the safety, compliance and pharmacokinetics of 1-month treatment of Isoniazid, Rifapentine and Vitamin B6 in renal transplant candidates.

Eligible Conditions

  • Latent Tuberculosis
  • End Stage Renal Disease (ESRD)
  • Renal Transplant Candidate for Right Kidney
  • Renal Transplant Candidate for Left Kidney

Treatment Effectiveness

Effectiveness Progress

3 of 3
This is further along than 93% of similar trials

Study Objectives

1 Primary · 2 Secondary · Reporting Duration: 2 years

2 years
Rate of reactivation of active tuberculosis
28 days
Pharmacokinetic parameters
Rate of adverse events with 1-m INH/RPT/Vit B6
Rate of treatment completion
Rate of treatment compliance

Trial Safety

Safety Progress

3 of 3
This is further along than 85% of similar trials

Trial Design

1 Treatment Group

1 month Rifapentine, Isoniazid and Vitamin B6
1 of 1
Experimental Treatment

25 Total Participants · 1 Treatment Group

Primary Treatment: 1 month Rifapentine, Isoniazid and Vitamin B6 · No Placebo Group · Phase 4

1 month Rifapentine, Isoniazid and Vitamin B6
Drug
Experimental Group · 1 Intervention: Rifapentine · Intervention Types: Drug
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Rifapentine
2002
Completed Phase 3
~1210

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 2 years

Trial Background

Prof. Pinki Bhatt, Assistant Professor
Principal Investigator
Rutgers, The State University of New Jersey
Closest Location: Pinki J Bhatt · New Brunswick, NJ
N/AFirst Recorded Clinical Trial
1 TrialsResearching Latent Tuberculosis
0 CompletedClinical Trials

Eligibility Criteria

Age 18+ · All Participants · 6 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You have a weight > 30 kg.
You are a living-related or deceased kidney transplant candidate.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.

References